TRVI

Trevi Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 4/10
  • Momentum↑ 8/10
Trevi Therapeutics sales and earnings growth
TRVI Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 15.91%
  • FCF Y/Y↓ -25.38%
Trevi Therapeutics gross and profit margin trends
TRVI Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -50.10%
Trevi Therapeutics net debt vs free cash flow
TRVI Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -45888.0

Trevi Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗